Trials / Completed
CompletedNCT02607332
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors (GIST). Recently, sunitinib (SuteneTM, Pfizer) showed activity as second-line therapy in GIST patients after failure with imatinib. However, virtually all patients will eventually progress or become intolerable after the first-line imatinib and the second-line sunitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2015-11-18
- Last updated
- 2020-01-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02607332. Inclusion in this directory is not an endorsement.